Norathyriol for Health & Longevity

Created on 11/13/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Norathyriol is a plant compound that gut bacteria release from mangiferin, the main compound of mango leaves; in animals it acts on the enzymes that handle blood sugar, blood fats and uric acid. It has never been given to people: every sign of benefit comes from cells, mice, rats or roundworms. Its safety is unstudied rather than demonstrated. Sold only as a laboratory chemical, it sits at the speculative end. (Full Review)

Protocol

No human regimen
None published
No practitioner protocol, guideline or trial regimen; sold for laboratory use only
The only human-tested route
Mangiferin 150 mg daily
12 weeks, placebo-controlled; gut bacteria release norathyriol from it
Doses used in animals
0.5–4.0 mg/kg
Rodent urate studies; 0.5–1 mg applied topically to mice
Time to effect
Blood triglycerides
12 weeks
Measured with mangiferin; unknown for norathyriol
Attention
3 hours
After a single 100 mg mango leaf extract dose; inconsistent signal
Uric acid
Unknown in people
Time dependence after single dosing in rodents

Benefits

Contraindications
  • Pregnant and breastfeeding women
  • People with a bleeding disorder, on anticoagulants, or facing surgery
  • People with a hormone-sensitive cancer, such as estrogen-receptor-positive breast cancer
  • People with inherited muscle calcium-channel disorders linked to RYR1, such as malignant hyperthermia susceptibility
  • Children and adolescents
Key Interactions
Theoretical (inferred from mechanism)
  • Urate-lowering drugs (allopurinol, febuxostat, probenecid)
  • Substrates of UGT1A3, UGT1A7 and UGT1A9 (mycophenolate, propofol, mefenamic acid)
  • P-glycoprotein substrates (digoxin, fexofenadine, vincristine)
  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, warfarin)
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)
  • Blood-pressure-lowering drugs (lisinopril, amlodipine)
  • Glucose-lowering drugs (metformin, glipizide, acarbose)
  • Estrogen-receptor-modulating drugs (tamoxifen, raloxifene)
  • Supplements with additive effects (berberine, fish oil, beetroot nitrate)
  • Supplements and herbs that raise exposure (Rhizoma Anemarrhenae preparations containing timosaponin B2)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Loss of short-chain-fatty-acid-producing gut bacteria, increased bleeding tendency, skeletal muscle calcium release, blood pressure lowering, estrogen receptor activation, interference with clearance of other substances

Monitoring

Marker Target Why
Serum uric acid 3.5–7.2 mg/dL Expected to change
Fasting glucose 70–99 mg/dL Expected to change
Serum triglycerides No established target; track change from own baseline Expected to change
ALT 7–55 U/L Liver safety check
Serum creatinine 0.6–1.3 mg/dL Kidney safety check

Cadence: Baseline before any exposure, repeat at 12 weeks, then every 6–12 months (common-practice interval) while exposure continues; earlier repeat if a result moves outside its reference range

Qualitative Assessment

  • Unusual bruising, gum bleeding or prolonged bleeding from minor cuts
  • Stool consistency and bloating
  • Muscle cramping, weakness or unusual fatigue after exertion
  • Lightheadedness on standing
  • Energy and mental clarity through the day